作为药物点的Giardia lamblia核素的分析:一篇评论
Carlos Gaona-López1, Ana Verónica Martínez-Vázquez2, Juan Carlos Villalobos-Rocha3
1Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
Pharmaceuticals (Basel, Switzerland)
|August 26, 2023
概括
全球导致腹的原因Giardia lamblia,由于当前药物的严重副作用,需要新的治疗方法. 这篇评论探讨了寄生虫的核细胞作为巨病的新治疗点.
科学领域:
- 寄生虫学的寄生虫学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 吉亚迪亚兰布利亚 (Giardia lamblia) 引起广泛的腹,在高收入国家由于移民而增加发病率.
- 现有的巨病治疗方法具有显著的基因毒性,致癌性和致病性副作用.
- 迫切需要新的治疗策略和目标来对抗这种寄生虫感染.
研究的目的:
- 审查关于Giardia lamblia中核细胞存在的历史和当前证据.
- 为了确定Giardia lamblia核中潜在的治疗点,包括ncRNA和蛋白质.
- 讨论针对Giardia lamblia潜在有效性的新兴药物.
主要方法:
- 对Giardia lamblia研究的文献综述.
- 对研究核细胞结构和功能在真核细胞中的研究的分析.
- 汇编关于新型药物候选剂对寄生虫感染的数据.
主要成果:
- 有证据支持Giardia lamblia.中核作为亚核的存在.
- 在Giardia lamblia核中提出了特定的ncRNA和蛋白质作为潜在的药物点.
- 几种试验性药物显示出治疗巨病的前景.
结论:
- 吉亚迪亚兰布里亚核素 (Giardia lamblia nucleolus) 是新型抗吉亚迪亚症疗法的一个有希望的,尚未探索的目标.
- 准核细胞组件可能会导致更安全,更有效的治疗巨病.
- 对核细胞生物学和药物开发的进一步研究对于对抗巨病至关重要.
更多相关视频
10:22Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
8.9K
12:11A Modified EPA Method 1623 that Uses Tangential Flow Hollow-fiber Ultrafiltration and Heat Dissociation Steps to Detect Waterborne Cryptosporidium and Giardia spp.
Published on: July 9, 2012
20.5K
相关概念视频
02:55The Nucleolus
8.9K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K
01:26Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K